Evidence map›Paper›PMID 29735709›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2018

Cell-based screen for discovering lipopolysaccharide biogenesis inhibitors.

Ge Zhang, Vadim Baidin, Karanbir S Pahil, Eileen Moison, David Tomasek, Nitya S Ramadoss, Arnab K Chatterjee, Case W McNamara, Travis S Young, Peter G Schultz and 2 more

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 104 citations in OpenAlex.

  1. Article
  2. Molecular Basis for the Activation ofJournal of the American Chemical Society · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Colon-Targeted Mucoadhesive PLGA Microspheres Loaded withMolecules (Basel, Switzerland) · 2025
    Article
  7. Article
  8. Functional loss ofFrontiers in microbiology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. The inactivation ofiScience · 2024
    Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Ge ZhangDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.
Vadim BaidinDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.ORCID 0000-0002-6257-1226
Karanbir S PahilDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.ORCID 0000-0003-0247-5934
Eileen MoisonDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.
David TomasekDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138.
Nitya S RamadossCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Arnab K ChatterjeeCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Case W McNamaraCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Travis S YoungCalifornia Institute for Biomedical Research, La Jolla, CA 92037.
Peter G SchultzCalifornia Institute for Biomedical Research, La Jolla, CA 92037; schultz@scripps.edu txm50@psu.edu kahne@chemistry.harvard.edu.
Timothy C MeredithDepartment of Microbiology and Immunobiology, Harvard Medical School, Boston, MA 02115; schultz@scripps.edu txm50@psu.edu kahne@chemistry.harvard.edu.
Daniel KahneDepartment of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138; schultz@scripps.edu txm50@psu.edu kahne@chemistry.harvard.edu.
Harvard University · USCalifornia Institute for Biomedical Research · USPennsylvania State University · US

Funding

Targeting bacterial cell wall biogenesis for the development of novel antimicrobU19AI109764 · NIAID · HARVARD MEDICAL SCHOOL · PI WALKER, SUZANNE · 2014 to 2018
$25.2M
Outer Membrane Biogenesis: New Antibiotic TargetsR01AI081059 · NIAID · HARVARD UNIVERSITY · PI Daniel Kahne · 2009 to 2026
$9.5M
Detoxification of Lumenal Endotoxin by Gut MicrobiotaR21AI138152 · NIAID · PENNSYLVANIA STATE UNIVERSITY, THE · PI MEREDITH, TIMOTHY C. · 2018 to 2019
$414k
NIAID NIH HHS R01 AI081059NIAID NIH HHS R21 AI138152NIAID NIH HHS U19 AI109764
6 · The paper itself

Abstract

New drugs are needed to treat gram-negative bacterial infections. These bacteria are protected by an outer membrane which prevents many antibiotics from reaching their cellular targets. The outer leaflet of the outer membrane contains LPS, which is responsible for creating this permeability barrier. Interfering with LPS biogenesis affects bacterial viability. We developed a cell-based screen that identifies inhibitors of LPS biosynthesis and transport by exploiting the nonessentiality of this pathway in

Indexed as

Acinetobacter baumanniiAnti-Bacterial AgentsATP-Binding Cassette TransportersBacterial ProteinsLipopolysaccharidesAnti-Bacterial AgentsATP-Binding Cassette TransportersBacterial ProteinsLipopolysaccharidesMsbA protein, BacteriaABC transporterAcinetobacterhigh-throughput screeningLPS biogenesisMsbA inhibitor

Identifiers

PMID29735709
PMCPMC6042065
OpenAlexW2800133837

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.